Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patients

AIDS

Volumn 18, Issue 2, 2004, Pages 334-337

  Ripamonti, Diego ^a   Arici, Claudio ^a   Pezzotti, Patrizio ^b   Maggiolo, Franco ^a   Ravasio, Laura ^a   Suter, Fredy ^a  

^a OSPEDALI RIUNITI   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; FEMININITY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; SERODIAGNOSIS; SEX DIFFERENCE; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RISK FACTORS;

EID: 1342310726     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200401230-00028     Document Type: Article

References (29)

1. van Roon EN, Verzijl JM, Juttman JR, Lenderink AW, Blans MJ, Egberts ACG. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquired Immune Defic Syndr Hum Retrovirol 1999; 20:290-294.
2. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14:499-507.
3. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Cozzi Lepri A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15:185-194.
4. Le Moing V, Hene G, Leport C, Leweden C, Duran S, Garré M, et al. Impact of discontinuation of initial protease inhibitor therapy on further vitological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34:239-247
5. Dorrucci M, Pezzotti P, Grisorio B, Minardi C, Muro SM, Vullo V, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001; 15:1733-1736
6. Kirstein L, Anastos K, Cohen M, Greenblatt R, Levine A, Minkoff H, et al. Patterns and predictors of antiretroviral switching among a large cohort of HIV-1 infected women: 1994-1999. In: XIIIth International AIDS Conference. Durban, South Africa, July 2000 [Abstract TuPeC3384].
7. Grant LA, Silverberg MJ, Palacio H, Minkoff H, Anastos K, Young MA, et al. Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS 2001; 15:2101-2108.
8. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study. J Infect Dis 2002; 185:1062-1069.
9. Girard PM, Guiguet M, Bollens D, Goderel I, Meyohas MC, Lecomte I, et al. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type-1 infected patients on triple-drug regimen. Clin Infect Dis 2000; 31:987-994.
10. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J Acquired Immune Defic Syndr Hum Retrovirol 2000; 23:236-245.
11. Hansel A, Bucher HC, Nuesch R, Battegay M. Reasons for discontinuation of first HAART in a cohort of protease inhibitor naïve HIV-infected patients. J Acquired Immune Defic Syndr 2001; 26:191-197.
12. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-1327.
13. Bassetti S, Battegay M, Furre H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J Acquired Immune Defic Syndr 1999; 21:114-119.
14. Wit FWNM, van Leeuwen R, Weverling CJ, Jurriaans S, Nauta K, Steingrover R, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one year follow up of a cohort of human immunodeficiency virus. J Infect Dis 1999; 179:790-798.
15. Schrooten W, Wilkins EG, Castro A, Finazzi R, Pelgrom J, Colebunders R. Stopping anti-retrovirals treatment. In: XIIIth International AIDS Conference. Durban, South Africa, July 2000 [Abstract WePeB4292].
16. Rodriguez-Rosado R, Garcià-Samaniego J, Soriano V. Hepatotoxicity after interruption of highly active antiretroviral therapy. AIDS 1998; 12:1256.
17. d'Arminio Monforte A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquired Immune Defic Syndr 2001; 28:114-123.
18. Sulkowski MS, Thomas DL, Chaisson R, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
19. Wit FWNM, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
20. Melvin DC, Lee JK, Belsey E, Arnold J, Murphy RL. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 2000; 14:463-465.
21. Pezzotti P, d'Arminio Monforte A, Bugarini R, Rezza G, Arici C, Angarano G, et al. Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values? Eur J Epidemiol. 2000; 16:919-926.
22. Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquired Immune Defic Syndr 2003; 32:452-461.
23. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16:1566-1568.
24. Thurman PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36:586-590.
25. George SL, Gebhardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquired Immune Defic Syndr 2002; 31:154-162.
26. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30:1307-1311.
27. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26:1393-1398.
28. Puoti M, Bonacini M, Spinetti A, Putzolu V, Govindarajan S, Zaltron S, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2001; 183:134-137.
29. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients: the Multivirc Group. Hepatology 1999; 30:1054-1048.